Education
About Us
Working with TipRanks
Follow Us
Alignment Healthcare (ALHC)
NASDAQ:ALHC
Top Page
Alignment Healthcare
(NASDAQ:ALHC)
Select Model
Select Model
Rating:60Neutral
Price Target:
$20.00
▲(8.40% Upside)
Action:ReiteratedDate:03/02/26
The score is driven primarily by improving fundamentals (rapid revenue growth, turnaround toward profitability, and sharply reduced leverage) and a strong, growth-oriented 2026 outlook from management. These positives are tempered by weak near-term technicals and limited valuation support given negative earnings and no dividend yield data.
Positive Factors
Rapid Membership Growth
Sustained ~30%+ annual membership growth materially expands the risk pool and revenue base, increasing scale economics. Larger membership supports better negotiating leverage with providers, spreads fixed tech and care-coordination costs, and underpins durable top-line growth and unit-cost improvements over time.
Strong Multi-year Revenue Growth and Profitability Momentum
Rapid multi-year revenue expansion combined with a move to slight operating profitability in 2025 indicates the business model is beginning to leverage scale. Persistent revenue growth improves margin leverage potential, enhances cash generation prospects, and increases visibility on sustainable operating income if utilization and cost controls persist.
Improved Balance Sheet and Cash Position
A materially de-risked capital structure and stronger equity base reduce refinancing and solvency risk, giving management flexibility to invest in growth, absorb cyclical utilization swings, and meet CMS capital or regulatory needs. This enhances long-term resilience and lowers probability of dilutive financing.
Negative Factors
Inconsistent and Thin Margins Historically
Persistently weak or inconsistent margins limit the company’s ability to self-fund expansion and reduce buffers against reimbursement or utilization shocks. Medicare Advantage margins are sensitive to medical and pharmacy cost trends; thin historical profitability raises execution risk when industry pressures intensify.
Uneven Cash Flow Track Record
Irregular operating and free cash flow complicate investment planning and increase the chance management must access external capital during stress periods. Even with 2025 improvement, the variability in cash generation reduces confidence in sustained funding for growth initiatives and margin improvements.
Exposure to Medicare Advantage Industry Disruption
Structural MA risks — regulatory changes, benchmark adjustments, and intensified competition — can materially affect revenue per member and benefit funding. Because Alignment’s economics rely on capitation and risk-adjusted payments, prolonged industry disruption could pressure membership growth, margins, and long-term predictability.
Alignment Healthcare (ALHC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.86B
Dividend YieldN/A
Average Volume (3M)2.67M
Price to Earnings (P/E)―
Beta (1Y)0.52
Revenue Growth47.39%
EPS Growth85.35%
CountryUS
Employees1,679
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Plans
Share Statistics
EPS (TTM)-0.05
Shares Outstanding204,296,500
10 Day Avg. Volume2,645,182
30 Day Avg. Volume2,668,238
Financial Highlights & Ratios
PEG Ratio54.31
Price to Book (P/B)21.81
Price to Sales (P/S)0.99
P/FCF Ratio34.56
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue0.90
Enterprise Value/Gross Profit7.54
Enterprise Value/Ebitda78.52
Forecast
1Y Price Target
$25.14Price Target Upside36.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)0.12
Revenue Forecast (FY)$5.21B
Alignment Healthcare Business Overview & Revenue Model
Company DescriptionAlignment Healthcare, Inc., a tech-enabled Medicare advantage company, operates consumer-centric health care platform. It provides customized health care in the United States to seniors and those who need it through its Medicare advantage plans. The company owns Medicare advantage plans in the states of California, North Carolina, and Nevada. It also coordinates and provides covered health care services, including professional, institutional, and ancillary services to members enrolled in certain benefit plans of unaffiliated Medicare Advantage Health Maintenance Organizations. The company was founded in 2013 and is based in Orange, California.
How the Company Makes MoneyAlignment Healthcare generates revenue primarily through its Medicare Advantage plans, which are funded by the federal government. The company receives monthly premiums from the Centers for Medicare & Medicaid Services (CMS) for each enrolled member, based on a risk-adjusted payment model. Additionally, ALHC may earn supplemental revenue through care coordination and management services, as well as partnerships with healthcare providers and hospitals that enhance service delivery and patient outcomes. The company’s focus on value-based care, which emphasizes quality and efficiency, allows it to potentially benefit from shared savings programs and incentive structures aligned with improving patient health while controlling costs.
Alignment Healthcare Earnings Call Summary
Earnings Call Date:Feb 26, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Apr 30, 2026
Earnings Call Sentiment Positive
The call communicated strong financial and operating progress: substantial membership and revenue growth, margin expansion, positive free cash flow, improved SG&A efficiency, market-quality achievements (100% 4+ star plans) and solid AEP momentum. Management acknowledged near-term headwinds from the final phase-in of V28, policy/rate uncertainty from CMS (advanced rate notice), and a higher first-year MBR driven by a heavier dual/LIS mix. Those risks were framed as manageable given the company’s clinically led model, technology platform and disciplined growth approach. Overall the positives (robust growth, profitability improvements, cash generation, and quality metrics) materially outweigh the moderate regulatory and mix-related lowlights.Q4-2025 Updates
Positive Updates
Strong Membership and Revenue Growth
Q4 health plan membership of 236,300 (≈25% YoY growth). Full-year membership up 25% YoY. Q4 revenue of $1.0B (44% YoY growth) and full-year revenue of $3.9B (46% YoY growth).
Profitability and Margin Expansion
Full-year adjusted EBITDA of $110M vs roughly breakeven in 2024 (adjusted EBITDA margin 2.8%), representing ~270 basis points of margin expansion year-over-year. Q4 adjusted EBITDA of $11M, outperforming guidance (vs. guidance of negative $9M to negative $1M).
Improved Medical Benefit Ratio and Adjusted Gross Profit
Full-year adjusted gross profit $495M with a consolidated MBR of 87.5%, an improvement of 130 basis points YoY. Q4 adjusted gross profit $125M and adjusted MBR of 87.7%.
Operational Leverage and SG&A Efficiency
Full-year adjusted SG&A $385M (28% increase YoY in absolute dollars) but SG&A as a percent of revenue declined from 11.1% to 9.7% (≈140 basis points improvement), reflecting operating leverage as membership scaled.
Cash Flow and Balance Sheet Strength
Generated positive free cash flow in 2025 and ended the year with $604M in cash and investments. Closed a $200M revolving credit facility (not expected to be drawn), supporting capital structure maturation.
Successful AEP / Early 2026 Momentum
January 2026 membership grew to 275,300 (31% YoY). Broad growth across markets: 23% growth in California and >80% growth in ex-California counties. Nearly 20% improvement in AEP voluntary disenrollment and ~80% of gross sales sourced from plan switchers.
Replicable Quality Across Markets (Star Ratings)
100% of members and plans rated 4 stars or above. Notable plan ratings include a 5-star plan in North Carolina (3rd consecutive year), two 5-star plans in Nevada, a 4.5-star plan in Texas and a 4-star plan in Arizona, demonstrating quality portability outside California.
Technology & Care Model Advantages
Continued emphasis on AIVA/AVA data platform and Care Anywhere clinical model to improve visibility, cost control and scalability; targeted midyear deployments of AI use cases and workflow improvements expected to accelerate efficiency and scale.
Updated 2026 Guidance
2026 guidance: membership 292k–298k; revenue $5.14B–$5.19B (midpoint ≈31% YoY growth); adjusted gross profit $615M–$650M (midpoint MBR ≈87.7%); adjusted EBITDA $133M–$163M. Membership guidance midpoint raised by 2,000 since prior 8-K.
Recognition and Brand Momentum
Named to Fortune Magazine's World's Most Admired Companies list for the first time, reflecting external validation of the company's senior care focus.
Negative Updates
Regulatory and Rate Uncertainty (Advanced Rate Notice / V28)
CMS advanced rate notice signaled a near-flat net rate environment (advanced notice referenced ~0.9% net), creating industry-wide concerns. Management flagged the third phase-in of the V28 risk model and potential risk-model rebasing as headwinds to MBR and pricing.
New Member Mix Pressure on MBR
2026 guidance contemplates a higher proportion of LIS/dual/C-SNP members (core to strategy) which carry higher first-year MBRs; Management noted year-1 mix contributes to upward pressure on MBR despite underlying operational improvements.
Policy Risk Around Chart Reviews and Program Integrity
Potential CMS policy changes (e.g., excluding unlinked chart reviews) and other program-integrity moves introduce uncertainty; while company exposure to chart reviews is limited (~1% of total HCC value, with an even smaller unlinked subset), policy shifts could affect the broader reimbursement environment.
Competitive & Distribution Dynamics
Industry disruption and competitors pulling back creates opportunities but also signals volatility; company is adjusting distribution/broker strategies and is still finalizing provider engagements in at least one targeted new-state expansion, which may delay or limit near-term expansion.
Seasonality and Part D / Utilization Headwinds
Management expects modestly lower MBR in first half of 2026 versus full-year average given Part C seasonality and a flatter Part D slope in 2026. Broader utilization pressures across the Medicare Advantage industry were called out as ongoing challenges.
Concentration of Growth Outside California Still Small
Ex-California membership more than doubled but remains ~38,000 members (~16% of total) and <4% market share across 23 counties outside California, indicating meaningful but early-stage expansion outside the home market.
Company Guidance
Alignment's initial 2026 guidance calls for year-end membership of 292,000–298,000, revenue of $5.14–5.19 billion (midpoint $5.16B, ~31% YoY growth), adjusted gross profit of $615–650 million (midpoint $633M, implied MBR ~87.7%), and adjusted EBITDA of $133–163 million (consistent with prior consensus near $145M); first‑quarter 2026 guidance is 281,000–285,000 members, $1.21–1.23 billion revenue, $138–148 million adjusted gross profit and $26–36 million adjusted EBITDA. Management noted the guide assumes H1 MBR modestly below the full‑year average and H2 slightly above, a flatter Part D slope, no assumption for sweep pickup (2025 sweep benefited adjusted gross profit/EBITDA by ≈$14M, ~30 bps to consolidated MBR), revenue PMPMs balanced by higher benchmarks and Part D direct subsidy offset by the final phase‑in of V28 and ex‑California mix, and continued SG&A leverage (2025 adjusted SG&A $385M, 9.7% of revenue) while building on 2025 results (FY 2025: 236,300 members, $3.9B revenue, $495M adjusted gross profit, MBR 87.5% (+130 bps), $110M adjusted EBITDA, 2.8% adj. EBITDA margin, $604M cash/investments).Alignment Healthcare Financial Statement Overview
Summary
Strong multi-year revenue growth and a clear improvement toward breakeven profitability in 2025, alongside a healthier balance sheet with sharply lower debt. Offsetting factors include still-thin and inconsistent margins, limited clarity from the reported 2025 gross profit/margin data point, and historically uneven cash-flow consistency despite the 2025 turnaround to positive operating and free cash flow.Income Statement
Revenue growth has been strong over the period (from ~$0.96B in 2020 to ~$3.95B in 2025), with a particularly large step-up in 2024. Profitability has materially improved: the company moved from sizable operating losses in 2021–2024 to slightly positive operating income in 2025, and net losses narrowed to near breakeven in 2025. Offsetting this, margins have been inconsistent and generally weak (net margin negative in most years, and 2025 profitability is still very thin), and the 2025 gross profit/margin appears to be reported as zero, which reduces visibility into core unit economics.56
Neutral
Balance Sheet
Leverage improved dramatically in 2025, with total debt falling sharply versus 2024 and debt relative to equity dropping to a very low level, which meaningfully de-risks the capital structure. Equity also increased versus 2024, supporting a stronger balance sheet profile. The main weakness is that returns on equity remain negative given the company is still slightly unprofitable, and the balance sheet showed elevated leverage as recently as 2024, indicating prior volatility in capital structure.68
Positive
Cash Flow
Cash generation strengthened meaningfully in 2025, with solid positive operating cash flow and positive free cash flow, a notable turnaround from negative free cash flow in 2021–2024. However, free cash flow declined year over year in 2025, and cash flow results have been uneven historically (including several years of negative operating cash flow), which lowers confidence in consistency. The relationship between cash flow and earnings is also distorted in loss years, so underlying sustainability should be monitored.62
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.95B | 2.70B | 1.82B | 1.43B | 1.17B |
| Gross Profit | 488.56M | 296.69M | 201.03M | 184.28M | 128.73M |
| EBITDA | 45.24M | -77.44M | -105.30M | -113.53M | -161.81M |
| Net Income | -724.00K | -128.03M | -148.02M | -149.55M | -195.29M |
Balance Sheet | |||||
| Total Assets | 1.07B | 782.06M | 591.88M | 633.86M | 630.89M |
| Cash, Cash Equivalents and Short-Term Investments | 577.94M | 470.65M | 318.82M | 409.55M | 466.60M |
| Total Debt | 338.07M | 329.26M | 170.79M | 164.60M | 157.59M |
| Total Liabilities | 886.51M | 681.11M | 433.81M | 394.56M | 324.84M |
| Stockholders Equity | 179.28M | 99.85M | 156.95M | 238.13M | 306.04M |
Cash Flow | |||||
| Free Cash Flow | 139.93M | -6.65M | -95.18M | -69.20M | -97.14M |
| Operating Cash Flow | 139.93M | 34.77M | -59.19M | -45.43M | -78.78M |
| Investing Cash Flow | -14.97M | 39.19M | -147.26M | -28.22M | -20.82M |
| Financing Cash Flow | 18.04M | 156.03M | 105.00K | 16.59M | 360.13M |
Alignment Healthcare Technical Analysis
Negative
18.45
Price Trends
20.92
Negative
19.39
Negative
17.16
Positive
Market Momentum
-0.59
Positive
39.02
Neutral
18.15
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALHC, the sentiment is Negative. The current price of 18.45 is below the 20-day moving average (MA) of 20.25, below the 50-day MA of 20.92, and above the 200-day MA of 17.16, indicating a neutral trend. The MACD of -0.59 indicates Positive momentum. The RSI at 39.02 is Neutral, neither overbought nor oversold. The STOCH value of 18.15 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ALHC.
Alignment Healthcare Risk Analysis
Alignment Healthcare disclosed 66 risk factors in its most recent earnings report. Alignment Healthcare reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Alignment Healthcare Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $4.07B | -8.51 | -44.51% | ― | 37.38% | -912.18% | |
60 Neutral | $3.86B | -88.83 | -0.52% | ― | 47.39% | 85.35% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $21.55B | -3.03 | -28.79% | ― | 14.92% | -286.72% | |
50 Neutral | $1.03B | -14.21 | -26.33% | ― | 15.23% | 38.79% | |
49 Neutral | $7.73B | 18.68 | 11.02% | ― | 13.71% | -18.02% | |
47 Neutral | $22.08B | 25.97 | 6.98% | 1.38% | 9.87% | -5.58% |
* Healthcare Sector Average
ALHC
Alignment Healthcare
18.45
2.64
16.70%
CNC
Centene
43.82
-15.18
-25.73%
HUM
Humana
181.58
-76.93
-29.76%
MOH
Molina Healthcare
144.81
-167.08
-53.57%
CLOV
Clover Health Investments
2.00
-1.83
-47.78%
OSCR
Oscar Health
13.67
-2.58
-15.88%
Alignment Healthcare Corporate Events
Business Operations and StrategyFinancial Disclosures
Alignment Healthcare Reports Strong Medicare Advantage Membership Growth
Positive
Jan 12, 2026
On January 12, 2026, Alignment Healthcare reported that its Medicare Advantage health plan membership rose 31% year over year to approximately 275,300 as of January 1, 2026, extending a roughly 30% compounded annual growth rate since its 2021 IPO and underscoring continued momentum in the MA market. Following a strong 2026 annual enrollment period, the company guided to 290,000 to 296,000 members by year‑end 2026 and said it expects consensus adjusted EBITDA of about $145 million in 2026 to fall within its forthcoming full‑year guidance range, while reaffirming its previously issued 2025 outlook for membership, revenue, adjusted gross profit and adjusted EBITDA; management highlighted that 100% of members remain in plans rated 4 stars or higher for the second consecutive year, reinforcing Alignment’s quality positioning and suggesting a supportive backdrop for continued scalable growth and shareholder value creation.
The most recent analyst rating on (ALHC) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Alignment Healthcare stock, see the ALHC Stock Forecast page.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.